Literature DB >> 10604640

Survival of patients with renovascular disease and ACE inhibition.

A Losito1, M Gaburri, R Errico, B Parente, P G Cao.   

Abstract

AIM: Renovascular hypertension (RVH) is associated with a high prevalence of target organ damage and a high mortality. We have undertaken this follow-up study to assess the role played by comorbid conditions, and pharmacological treatment on survival, and on renal function in 64 patients with diffuse atherosclerotic vascular and renovascular disease (RVD). PATIENTS AND METHODS: The patients were followed for an average period of 37.3+/-20.4 months.
RESULTS: At the end of the follow-up we found a cumulative survival at 5 years of 60%+/-10. Cerebrovascular and cardiovascular disease were responsible for 92% of deaths. A decrease in creatinine clearance >10 ml/min at 5 years was found in 65% of patients, 3 of whom ended in dialysis. Multivariate analysis of predictors of survival showed that treatment with angiotensin converting enzyme inhibitors (ACEi) was significantly associated with a favourable outcome (p = 0.019). Conversely, proteinuria had a negative effect. Renal survival was best predicted by the level of renal function at entry (p = 0.02), and was not influenced by pharmacological treatment.
CONCLUSION: We conclude that ACEi exerts a beneficial effect on survival without affecting renal function in patients with RVD due to unilateral renal stenosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10604640

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  4 in total

Review 1.  Timing and selection for renal revascularization in an era of negative trials: what to do?

Authors:  Stephen C Textor; Michael M McKusick; Sanjay Misra; James Glockner
Journal:  Prog Cardiovasc Dis       Date:  2009 Nov-Dec       Impact factor: 8.194

Review 2.  Renovascular hypertension and ischemic nephropathy.

Authors:  Stephen C Textor; Lilach Lerman
Journal:  Am J Hypertens       Date:  2010-09-23       Impact factor: 2.689

Review 3.  Renovascular hypertension update.

Authors:  Stephen C Textor
Journal:  Curr Hypertens Rep       Date:  2006-12       Impact factor: 5.369

Review 4.  Renal artery stenosis and cardiovascular risk.

Authors:  Shahzad Shafique; Aldo J Peixoto
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-03       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.